• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by GRAIL Inc.

    8/30/24 5:20:33 PM ET
    $GRAL
    Medical Specialities
    Health Care
    Get the next $GRAL alert in real time by email
    S-8 1 forms-8.htm S-8 Document
    As filed with the Securities and Exchange Commission on August 30, 2024
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    GRAIL, Inc.
    (Exact name of Registrant as specified in its charter)
    Delaware86-3673636
    (State or other jurisdiction of incorporation or organization)
    (I.R.S. Employer Identification Number)
    1525 O’Brien Drive
    Menlo Park, California
    94025
    (Address of Principal Executive Offices)(Zip Code)
    2024 Employment Inducement Incentive Award Plan
    (Full Title of the Plan)

    Abram Barth
    General Counsel and Secretary
    GRAIL, Inc.
    1525 O’Brien Drive
    Menlo Park, California 94025
    (Name and Address of Agent for Service)

    (833) 694-2553
    (Telephone Number, Including Area Code, of Agent for Service)
    Copies to:
    W. Alex Voxman
    Ross McAloon
    Latham & Watkins LLP
    355 South Grand Avenue, Suite 100
    Los Angeles, California 90071
    (213) 485-1234
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer☐Accelerated filer☐
    Non-accelerated filer☒Smaller reporting company☐
    Emerging growth company☒
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒



    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed by GRAIL, Inc., a Delaware corporation (the “Registrant”), with the U.S. Securities and Exchange Commission (the “Commission”) for the purpose of registering 500,000 shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”), that may be offered or issued under the Registrant’s 2024 Employment Inducement Incentive Award Plan (the “Inducement Plan”) adopted by the Registrant’s board of directors on August 9, 2024. The Inducement Plan provides for, among other things, the grant of stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalents or other stock or cash based awards to eligible individuals.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Item 1. Plan Information

    Not required to be filed with this Registration Statement.


    Item 2. Registrant Information and Employee Plan Annual Information

    Not required to be filed with this Registration Statement.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference

    The following documents or designated portions thereof filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

    (1)
    The Registrant’s effective Registration Statement on Form 10 (File No. 001-42045) filed with the Commission on June 3, 2024 (the “Form 10”);

    (2)
    The Registrant’s Quarterly Report on Form 10-Q filed on August 13, 2024;
    (3)
    The Registrant’s Current Reports on Form 8-K filed on June 3, 2024 (as amended by the Current Report on Form 8-K/A filed by the Registrant on June 6, 2024), June 12, 2024, June 24, 2024 (as amended by the Current Report on Form 8-K/A filed by the Registrant on July 2, 2024) and June 27, 2024; and
     
    (4)
    The description of the Registrant’s Common Stock contained in the Information Statement filed as Exhibit 99.1 to the Form 10, including any amendments or supplements thereto.

    All reports and documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the



    extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 4. Description of Securities

    Not applicable.

    Item 5. Interests of Named Experts and Counsel

    Not applicable.

    Item 6. Indemnification of Directors and Officers

    The Registrant is governed by the General Corporation Law of the State of Delaware (the “Delaware General Corporation Law”). Section 145 of the Delaware General Corporation Law provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys’ fees), judgments, fines, and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending, or completed actions, suits, or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee, or agent to the Registrant. The Delaware General Corporation Law provides that Section 145 is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors, or otherwise. The Registrant’s certificate of incorporation provides for indemnification by the Registrant of its directors, officers, and employees to the fullest extent permitted by the Delaware General Corporation Law. The Registrant has entered, or will enter, into indemnification agreements with each of its current directors, executive officers, and certain other officers to provide these directors and officers additional contractual assurances regarding the scope of the indemnification set forth in the Registrant’s certificate of incorporation and bylaws, and to provide additional procedural protections.

    Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director or officer of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, except for liability (i) for any breach of the director’s or officer’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) in the case of directors, for unlawful payments of dividends or unlawful stock repurchases, redemptions, or other distributions, or (iv) for any transaction from which the director or officer derived an improper personal benefit, provided that officers may not be indemnified for actions by or in the right of the corporation. The Registrant’s certificate of incorporation provides for such limitation of liability.

    The Registrant maintains standard policies of insurance under which coverage is provided (a) to its directors and officers against loss rising from claims made by reason of breach of duty or other wrongful act and (b) to the Registrant with respect to payments that may be made by the Registrant to such officers and directors pursuant to the above indemnification provision or otherwise as a matter of law.

    See also the Undertakings set forth in the response to Item 9 herein.

    Item 7. Exemption from Registration Claimed

    Not applicable.



    Item 8. Exhibits
    Exhibit
    Number
    Exhibit DescriptionFormIncorporated by Reference
    Date
    Number
    Filed
    Herewith
    4.1
    Certificate of Incorporation of GRAIL, Inc.
    S-806/21/20244.1
    4.2
    Bylaws of GRAIL, Inc.
    S-806/21/20244.2
    5.1
    Opinion of Latham & Watkins LLP
    X
    23.1
    Consent of Independent Registered Public Accounting Firm
    X
    23.2
    Consent of Latham & Watkins LLP (included in Exhibit 5.1)
    X
    24.1
    Power of Attorney (included on signature page)
    99.1(a)#
    2024 Employment Inducement Incentive Award Plan
    X
    99.1(b)#
    Form of Restricted Stock Unit Award Grant Notice under the 2024 Employment Inducement Incentive Award Plan
    X
    107.1
    Registration Fee Table
    X
    #Indicates management contract or compensatory plan.

    Item 9. Undertakings

    (a) The Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective registration statement; and

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement.

    (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.





    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (h) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.





    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Menlo Park, State of California, on August 30, 2024.
     
    GRAIL, INC.
    By: /s/ Robert Ragusa
     Name: Robert Ragusa
     Title: Chief Executive Officer
    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Robert Ragusa, Abram Barth and Donald Lang, and each of them, with full power of substitution and full power to act without the other, as his true and lawful attorney-in-fact and agent to act for him in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file this Registration Statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated. 

    Signature Title Date
    /s/ Robert RagusaDirector and Chief Executive Officer August 30, 2024
    Robert Ragusa
     
    (Principal Executive Officer)
     
    /s/ Aaron Freidin
    Chief Financial Officer
    August 30, 2024
    Aaron Freidin
     
    (Principal Financial Officer and
    Principal Accounting Officer)
     
    /s/ William (Bill) Chase 
    Director
     August 30, 2024
    William (Bill) Chase
    /s/ Steve Mizell
    Director
    August 30, 2024
    Steve Mizell
      
    /s/ Gregory Summe
     
    Director
     August 30, 2024
    Gregory Summe



    Get the next $GRAL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GRAL

    DatePrice TargetRatingAnalyst
    12/2/2025$110.00Equal-Weight
    Morgan Stanley
    11/12/2025$100.00Neutral → Buy
    Guggenheim
    4/21/2025$32.00Buy
    Canaccord Genuity
    11/27/2024$16.00Equal-Weight
    Morgan Stanley
    11/15/2024Peer Perform
    Wolfe Research
    10/17/2024Neutral
    Guggenheim
    More analyst ratings

    $GRAL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

    FDA Submission Marks a Pivotal Milestone in Advancing Early Cancer Detection, Addressing Unmet Needs in Cancer Screening MENLO PARK, Calif., Jan. 29, 2026  /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the submission of the final module of the Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its Galleri® multi-cancer early detection (MCED) test. The FDA designated the test as a Breakthrough Device in 2018. "Cancer is now the leading killer of a

    1/29/26 7:25:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL to Present at the 44th Annual J.P. Morgan Healthcare Conference

    MENLO PARK, Calif., Dec. 15, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 12 at 7:30 a.m. PT.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event. About GRAILGRAIL is a healthcare company whose mission

    12/15/25 4:01:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    MENLO PARK, Calif., Dec. 1, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 21,570 shares of GRAIL's common stock to 21 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

    12/1/25 4:01:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chase William J was granted 213 shares, increasing direct ownership by 0.58% to 36,803 units (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    1/16/26 4:58:25 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Director Summe Gregory L was granted 329 shares, increasing direct ownership by 0.85% to 39,123 units (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    1/16/26 4:57:19 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Director Mizell Steven was granted 206 shares, increasing direct ownership by 0.56% to 36,675 units (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    1/16/26 4:55:42 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on GRAIL with a new price target

    Morgan Stanley resumed coverage of GRAIL with a rating of Equal-Weight and set a new price target of $110.00

    12/2/25 8:25:57 AM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL upgraded by Guggenheim with a new price target

    Guggenheim upgraded GRAIL from Neutral to Buy and set a new price target of $100.00

    11/12/25 8:52:59 AM ET
    $GRAL
    Medical Specialities
    Health Care

    Canaccord Genuity initiated coverage on GRAIL with a new price target

    Canaccord Genuity initiated coverage of GRAIL with a rating of Buy and set a new price target of $32.00

    4/21/25 8:38:45 AM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    SEC Filings

    View All

    GRAIL Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - GRAIL, Inc. (0001699031) (Filer)

    1/12/26 10:30:19 AM ET
    $GRAL
    Medical Specialities
    Health Care

    SEC Form 144 filed by GRAIL Inc.

    144 - GRAIL, Inc. (0001699031) (Subject)

    12/3/25 4:31:09 PM ET
    $GRAL
    Medical Specialities
    Health Care

    SEC Form SCHEDULE 13G filed by GRAIL Inc.

    SCHEDULE 13G - GRAIL, Inc. (0001699031) (Subject)

    11/24/25 7:25:56 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ding Chun R bought $1,024,698 worth of shares (78,829 units at $13.00) and acquired $879,900 worth of shares (70,000 units at $12.57) (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    10/10/24 7:45:32 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Leadership Updates

    Live Leadership Updates

    View All

    GRAIL Appoints Sarah Krevans to Board of Directors

    MENLO PARK, Calif., Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Ms. Krevans will also serve as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Governance Committee. Following the appointment of Ms. Krevans, the Board will be composed of five directors, four of whom are independent. Ms. Krevans served as president and CEO of Sutter Health, a Northern

    10/21/24 4:01:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Wheels Up Announces Gregory Summe to Join Board of Directors

    Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

    8/8/24 8:05:00 AM ET
    $AVTR
    $GRAL
    $NXPI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care

    $GRAL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by GRAIL Inc.

    SC 13G - GRAIL, Inc. (0001699031) (Subject)

    11/14/24 3:35:14 PM ET
    $GRAL
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by GRAIL Inc.

    SC 13G - GRAIL, Inc. (0001699031) (Subject)

    11/12/24 4:47:47 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by GRAIL Inc.

    SC 13G/A - GRAIL, Inc. (0001699031) (Subject)

    9/30/24 6:42:39 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Financials

    Live finance-specific insights

    View All

    GRAIL Reports Third Quarter 2025 Financial Results

    Q3 U.S. Galleri Revenue Grew 28% Year-Over-Year to $32.6 Million Q3 Galleri Tests Sold Grew 39% Year-Over-Year to More Than 45,000 Galleri PMA Submission to FDA Now Anticipated in Q126 Cash Position of More Than $850 Million Includes Recently Completed Private Placement MENLO PARK, Calif., Nov. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter of 2025. Total revenue in the third quarter grew 26% year-over-year to $36.2 million

    11/12/25 4:02:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL to Announce Third Quarter 2025 Financial Results

    Analyst Day 2025 Webcast to Begin at 11:00 a.m. ET on November 13th MENLO PARK, Calif., Oct. 29, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2025 following the close of market on Wednesday, Nov. 12, 2025. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress. Third Quarter 2025 Webcast and Conference Call DetailsA link

    10/29/25 4:02:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    /U P D A T E -- GRAIL, Inc./

    In the news release, GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings, issued 17-Oct-2025 by GRAIL, Inc. over PR Newswire, we are advised by the company that updated media assets have been attached to the news release. The complete, updated release follows: GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings More Than Half of Cancers Detected by Galleri Were Early Stage Approximately Three-Quarters of Galleri-Detected Cancers Do N

    10/17/25 6:08:00 PM ET
    $GRAL
    Medical Specialities
    Health Care